**Supplementary Table 1.** **Summary of IBD consensus guideline recommendations for infectious disease screening in patients before starting immunomodulatory therapy**

|  |  |  |
| --- | --- | --- |
| Reference | **Recommended** before starting  | **Could be considered** before starting  |
| D’Haens([16](#_ENREF_16)) | TB, HBV, HIV |  |
| Turner([39](#_ENREF_39)) | TB | HBV, HCV,VZV |
| Le Saux([12](#_ENREF_12)) | TB, VZVa |  |
| Veereman-Wauters([13](#_ENREF_13)) | TB, HBV |  |
| Rahier([15](#_ENREF_15)) | TB, HBV, HIV, VZVa | EBV, HCV |
| Ruemmele([191](#_ENREF_191)) | TB, HBVb |  |
| Calvet([71](#_ENREF_71)) | TB, HBV, HCV |  |
| Nordgaard-Lassen([192](#_ENREF_192)) | TB , HBV, VZVa |  |
| This clinical report | TB, HBV, HIV, VZV | HCV (based on risk factor assessment) |
| **Tuberculosis (TB)-specific screening** |
| Reference | Year | TB screening suggestions |
| D’Haens([16](#_ENREF_16)) | 2010 | TB screening per local guidelines |
| Turner([39](#_ENREF_39)) | 2011 | TB testing (NOS), CXR |
| Le Saux([12](#_ENREF_12)) | 2012 | Risk factors, TST, CXR, consider IGRA |
| Veereman-Wauters([13](#_ENREF_13)) | 2012 | Risk factors, possible CXR |
| Rahier([15](#_ENREF_15)) | 2013 | Patient history, CXR, TST, IGRA |
| Ruemmele([191](#_ENREF_191)) | 2014 | CXR, TST and/or IGRA |
| Calvet([71](#_ENREF_71)) | 2013 | Two consecutive TST or CXR and IGRA |
| Solovic([89](#_ENREF_89)) | 2010 | Summary of all guidelines, TB screening per local guidelines |
| Nordgaard-Lassen([192](#_ENREF_192)) | 2012 | Risk factors, CXR and IGRA (TST if IGRA cannot be done) |
| This clinical report | 2015 | Risk factors, TST and IGRA; if any positive CXR |

TB, tuberculosis; HBV, hepatitis B virus; HCV, hepatitis C virus, HIV, human immunodeficiency virus; VZV, varicella zoster virus; EBV, Epstein Barr virus; NOS, not otherwise specified; TST, tuberculin skin test; CXR, chest x-ray; IGRA, interferon-gamma release assay